Investorideas.com

Get great ideas from our AI, cannabis, cleantech, crypto, esports and mining podcasts - be a guest or sponsor : 800 665 0411

 


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology, telemedicine, Covid-19

Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech stocks - Feature Your Company & Product Here

Biotech News

FDA Grants Ampio Pharma IND and Approves Phase 1 Trial for Inhaled Ampion in COVID-19 Patients
September 22, 2020 (Investorideas.com Newswire) Ampio Pharmaceuticals traded 15% higher reaching a new 52-week high after the company reported that the U.S. FDA granted an IND and approved the clinical trial protocol for inhaled Ampion for use in COVID-19 patients with respiratory distress.

Healthcare Startups Raised $111.4bn in Total Funding, a 34% Jump Year-on-Year
September 22, 2020 (Investorideas.com Newswire) The coronavirus pandemic put enormous pressure on the healthcare industry, forcing pharmaceutical giants and institutions to roll out clinical trials for a COVID-19 vaccine at breakneck speed.

Sorrento Receives FDA Clearance to Proceed with Phase 1 COVID-19 Neutralizing Antibody Trial
September 18, 2020 (Investorideas.com Newswire) Sorrento Therapeutics shares traded more than 10% higher after the company reported it received FDA approval to proceed with its Phase 1 clinical trial of STI-1499 (COVI-GUARD) Neutralizing Antibody in hospitalized COVID-19 patients.

Investor Ideas Adds New Biotech (Nasdaq: ACER) (Nasdaq: AIKI) (Nasdaq: JAN) (TSXV: MDP) and Gaming / eSport Stocks (Nasdaq: SLGG)
Point Roberts, WA and Delta, BC - September 18, 2020 (Investorideas.com Newswire) Investorideas.com, a global news source and leading retail investor resource announces its weekly roundup of stocks added to its free global stock directories; biotech, gaming and eSport.

Marinus Pharma Shares Sail 50% Higher on Phase 3 Genetic Epilepsy Trial Results
September 17, 2020 (Investorideas.com Newswire) Marinus Pharmaceuticals shares reached a new 52-week high price after the company reported it achieved the primary endpoint in its Phase 3 Study of ganaxolone for CDKL5 deficiency disorder, a rare type of genetic epilepsy.

Amwell, with $100 Million Google Investment and Access to 80 Million Patients, Expected to Begin Trading on NYSE Sept. 17
September 17, 2020 (Investorideas.com Newswire) Virtual care company American Well Corp., which operates under the name Amwell, is expected to begin trading on the New York Stock Exchange on Thursday, September 17, under the symbol AMWL.

Check your financial plans are 'negative interest rate ready': deVere CEO
September 17, 2020 (Investorideas.com Newswire) Data presented by Buy Shares indicates that five selected leading public health care companies have cumulatively lost $65.59 billion in market capitalization. The slump is on a Year-to-Date basis.

Immunomedics' Shares Double on Gilead's $21 Billion Buyout Offer
September 15, 2020 (Investorideas.com Newswire) Shares of Immunomedics Inc. traded 100% higher after the company reported that it has agreed to be acquired by Gilead Sciences for $88 per share in cash.

Former CEO of Aethlon Medical, (NASDAQ: $AEMD) Leads new Medtech Company Sigyn Therapeutics; Company Merges into Reign Resources Corporation (OTCMARKETS: $RGNP)
LOS ANGELES, CA - September 11, 2020 (Investorideas.com Newswire) Breaking Medical Tech/ Covid- 19 stock news - Reign Resources Corporation ("Reign") (OTCMARKETS: RGNP) announced today that the Company has approved a share exchange agreement with Sigyn Therapeutics, Inc., a privately held medical technology company focused on the treatment of life-threatening inflammatory conditions.

Intra-Cellular Shares Soar on Positive Bipolar Depression Study Findings
September 10, 2020 (Investorideas.com Newswire) Shares of Intra-Cellular Therapies traded 77% higher after the company reported that positive data from its Phase 3 Study 402 will form the basis for its sNDA for lumateperone in treating bipolar depression in patients with Bipolar I or II disorder as monotherapy and adjunctive therapy.

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Sponsored Financial Content and Guest Posts

Buy a guest post on Investorideas.com

Biotech News from Newsfile

RETRANSMISSION: Bee Vectoring Technologies Successfully Completes Phase 2 Evaluations of Biological Products for In-licensing and Revenue Extension
Mississauga, Ontario and Sacramento, California--(Newsfile Corp. - September 22, 2020) -  Bee Vectoring Technologies International Inc. (CSE: BEE) (OTCQB: BEVVF) (CVE: BEE) (the "Company" or "BVT")  announced today that it has reached another important milestone in its ability to unlock new revenue streams through third-party product in-licensing, having successfully concluded Phase 2 evaluations. Following Phase 1 testing of six products, the Company completed a Phase 2 proof-of-concept field trial with two biological insecticides in North America. Field trials...

All American Aires Products Now Available at Sears.com and Kmart.com
Toronto, Ontario--(Newsfile Corp. - September 22, 2020) - American Aires Inc. (CSE: WIFI) (the "Company" or "Aires") is pleased to announce the immediate availability of all Aires products on Sears.com and Kmart.com.With Sears.com and Kmart.com, Aires is exposed to one of the largest marketplaces in United States with over than 16 million visitors every month.Aires will also have the opportunity to email more than 130 million active Sears and Kmart members, for promotion events,...

Bee Vectoring Technologies Successfully Completes Phase 2 Evaluations of Biological Products for In-licensing and Revenue Extension
Mississauga, Ontario and Sacramento, California--(Newsfile Corp. - September 22, 2020) - Bee Vectoring Technologies International Inc. (CSE: BEE) (OTCQB: BEVVF) (CVE: BEE) (the "Company" or "BVT") announced today that it has reached another important milestone in its ability to unlock new revenue streams through third-party product in-licensing, having successfully concluded Phase 2 evaluations. Following Phase 1 testing of six products, the Company completed a Phase 2 proof-of-concept field trial with two biological insecticides in North America. Field...

BiocurePharm, Korea ("BPK") Signs MOU With S&B Biopharm Enabling Expansion Into The European CAR T Market
Vancouver, British Columbia--(Newsfile Corp. - September 21, 2020) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") BiocurePharm, Korea ("BPK"), a subsidiary of Biocure Technology Inc. ("CURE") is pleased to announce that BPK has entered into a non-binding MOU with S&B Biopharm ("SRB") located in Sofia, Bulgaria. This agreement will allow BPK to locally manufacture CD-19 CAR T in Bulgaria and sell to the Eastern European market, including Poland, Turkey and Bulgaria. Expansion...

MustGrow Appoints Seasoned Social Impact Financier Barry Palte as Global Advisor
Saskatoon, Saskatchewan--(Newsfile Corp. - September 17, 2020) - MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company", "MustGrow") is pleased to announce the appointment of seasoned global social impact financier Barry Palte to its advisory team. Barry will leverage his extensive global relationships in sustainable and innovative ag-tech to support the global rollout of MustGrow's remarkably safe and effective mustard-derived crop protection products.Barry is a global investment markets expert with a passion for...

Subscribe to Biotech News